424 related articles for article (PubMed ID: 29535070)
1. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
Conte M; De Palma R; Altucci L
Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
4. Natural Agents-Mediated Targeting of Histone Deacetylases.
Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
[TBL] [Abstract][Full Text] [Related]
5. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
6. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
Schobert R; Biersack B
Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator.
Karati D; Mukherjee S; Roy S
Med Oncol; 2024 Mar; 41(4):84. PubMed ID: 38438564
[TBL] [Abstract][Full Text] [Related]
12. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitors in Tumor Immunotherapy.
Zhao LM; Zhang JH
Curr Med Chem; 2019; 26(17):2990-3008. PubMed ID: 28762309
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer.
Stazi G; Fioravanti R; Mai A; Mattevi A; Valente S
Curr Opin Chem Biol; 2019 Jun; 50():89-100. PubMed ID: 30986654
[TBL] [Abstract][Full Text] [Related]
17. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
18. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
